Gene hunt aims to unlock NF1's mysteries
NCT ID NCT00111384
First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 10 times
Summary
This study looks at people with neurofibromatosis type 1 (NF1) and their families to find out why some have more severe symptoms than others. Researchers will collect medical history, blood samples, and images to study genes and physical traits. The goal is to identify genes that influence disease severity and better understand rare features of NF1.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify genes that predict the severity of NF1, leading to better monitoring and personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve health outcomes, and results may take years to apply in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
313 people
The number who actually took part.
- Started
-
Jul 2005
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals with the genetic disorder Neurofibromatosis Type 1
- Ages
-
2 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: Group A: All affected individuals in a family who are post-pubertal male and female individuals and who meet the 1988 NIH criteria for neurofibromatosis type 1 (NIH Consensus Development Conference 1988). Group B: Unaffected individuals greater than 2 years of age who are relatives of participants (especially parents, but also siblings) are eligible to enroll and are critical to the success of the study. These individuals may be of any gender and ethnicity. If the individual is pre-pubertal, s/he must have a brief evaluation at the NIH Clinical Center (abbreviated medical history and skin and eye exam) to ensure s/he is not affected with NF1. Group C: individuals with unique or under-recognized features of NF1 of any age, gender or ethnicity and must have a correct clinical diagnosis of NF1 (NIH Consensus Development Conference 1988). all Group C participants enrolling in the study identify a physician who will be responsible for follow-up care so this can be arranged (if needed) at the conclusion of the evaluation at NIH. For healthy normal volunteers used for MRI imaging of the spine, we will aim to recruit one male and one female from each of 5 decades (18-30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years). These individuals may be of any ethnicity. Additional requirements include: 1. If female and of child-bearing age, must be willing to have a serum pregnancy test (HCG) and 2. Willingness to undergo a brief, focused history and physical exam to rule out occult spine pathology and to verify there are no contra-indications to spinal MRI imaging. EXCLUSION CRITERIA: EXCLUSION CRITERIA FOR GROUP A INDIVIDUALS INCLUDE: 1. Any history of administration (or current use) of radiation therapy, chemotherapeutic agents or biologic agents (experimental or not) that resulted in a documented significant change in spinal neurofibroma tumor burden or growth. 2. Any history of administration (or current use) of medication that might reasonably be expected to alter the natural history of tumor growth (examples include pirfenidone, interferon, farnesyl transferase inhibitor (FTI), MTX/VBL, thalidomide, growth hormone) or cause significant changes in gene expression profile. 3. Any history of surgery to significantly debulk spinal neurofibromas 4. Pregnancy/Lactation. If an affected pregnant or lactating woman is eligible for participation, we will request that she enroll after the conclusion of the pregnancy or lactation. 5. Cognitive delay in an adult or minor to the extent that sedation is required to obtain MRI. 6. Presence or suspected presence of hardware (Harrington rods) or metallic objects (e.g. shrapnel, aneurysm clips) or history of exposure to such objects (e.g. welding) that preclude MRI imaging. 7. Inability or unwillingness to tolerate a 1-hour (or more) MRI protocol. 8. Patients will be excluded if they cannot travel to the NIH because of their medical condition OR are less than 2 years of age. The PI may decline to enroll a patient for other reasons. EXCLUSION CRITERIA FOR GROUP B INDIVIDUALS INCLUDE: 1\) A non-affected pregnant or lactating woman in a family for whom LCL immortalization will not be performed may participate. However, if she is a member of a multi-affected family (and thus her blood will be used to prepare LCLs) we will request that she donate a blood sample at the conclusion of her pregnancy or upon the weaning of her child. EXCLUSION CRITERIA FOR GROUP C INDIVIDUALS INCLUDE: 1\) Less than 2 years of age. EXCLUSION CRITERIA FOR HEALTHY, NORMAL VOLUNTEERS INCLUDE: 1. Pregnancy or lactation (a serum HCG level will be drawn on all child-bearing age women). Women unwilling to have a serum pregnancy test cannot participate. 2. Any history of spine surgery or significant spinal disease (severe arthritis, autoimmune disorders, severe scoliosis, kyphosis or lordosis, cancer, NF1, NF2, or schwannomatosis) 3. Any active spine-related complaints: e.g. persistent back pain, radicular symptoms 4. Clinically significant medical condition that, in the opinion of the investigator, would compromise the patient's safety or affect his/her MRI (e.g., diabetes mellitus, chronic hypertension, severe anemia, kidney disease, heart disease \[angina, arrhythmias, congestive heart failure\]). 5. Previous eye surgery of any kind. 6. Inability to provide informed consent. 7. Permanent tattooed makeup (eyeliner, lip, etc) or general tattoos. Subjects with tattoos will be excluded if those are in a dangerous location in the body or made with colors (e.g. dark blue and dark green) whose content in iron cannot be definitely ruled out by the Investigators. 8. Any non-organic implant or any other device such as: cardiac pacemaker, insulin infusion pump, implanted drug infusion device, cochlear, otologic, or ear implant, transdermal medication patch (Nitro, hormones) that may cause problems if removed even temporarily, any metallic implants or objects, body piercing(s), bone/joint pin, screw, nail, plate, wire sutures or surgical staples, shunt. 9. Cerebral or other aneurysm clips. 10. Shrapnel or other metal imbedded in the subject's body (such as from war wounds or accidents). 11. Previous work in metal fields or with machines that may have left any metallic fragments in or near the subject's eyes. 12. A severe auto accident in the past so if it is uncertain whether any metal may still be imbedded in the subject's body. 13. Any psychological contraindications for MRI (e.g., suffer from claustrophobia). This will be assessed at the time when the medical history will be collected. 14. Any contraindications to having study procedures done. 15. Dental work such as crowns or bridges with indeterminate metals 16. The PI may decline to enroll a patient for other reasons.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Legius syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- Antioxidant drug shows promise for kids with NF1
- Can a simple walk test spot motor trouble in kids with NF1?
- New drug aims to help kids with rare genetic short stature grow taller
- New study tracks Long-Term safety of NF1 drug in kids